Sign In
Buy EXEL
$51.60
+3.06 (+6.30%)
At Close: Jun 03, 2026
Exelixis to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025
04:05pm, Monday, 06'th Jan 2025
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company's President and Chief Executive Officer, will provide a corporate overview
Exelixis Stock Surges 50% in a Year: Is There Room for Further Growth?
02:50pm, Monday, 06'th Jan 2025
EXEL's shares surge 50% in a year on the back of the strong performance of its lead drug Cabometyx. We are optimistic about the stock as we believe there is room for further growth.
EXEL vs. INCY: Which Stock Should Value Investors Buy Now?
12:41pm, Wednesday, 25'th Dec 2024
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and Incyte (INCY). But which of these two stocks is more attractive to value investo
Exelixis downgraded to Market Perform from Outperform at BMO Capital
04:15pm, Thursday, 19'th Dec 2024
BMO Capital downgraded Exelixis to Market Perform from Outperform with a price target of $40, up from $36. The "main driver of our thesis has played out positively," as a judge ruled in the MSN II lit
4 Biotech Stocks Most Wall Street Analysts Are Bullish About
02:25pm, Thursday, 19'th Dec 2024
Here, we present four biotech stocks, namely SRPT, ADMA, EXEL and ALNY, which most Wall Street analysts are optimistic about. These companies have upside potential for 2025, backed by strong fundament
Exelixis (EXEL) is an Incredible Growth Stock: 3 Reasons Why
01:46pm, Monday, 09'th Dec 2024
Exelixis (EXEL) is well positioned to outperform the market, as it exhibits above-average growth in financials.
EXEL or INCY: Which Is the Better Value Stock Right Now?
12:46pm, Monday, 09'th Dec 2024
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and Incyte (INCY). But which of these two stocks is more attractive to value investors?
2 Biotech Stocks to Buy Hand Over Fist in December
08:45am, Saturday, 07'th Dec 2024
The biotech industry has lagged the broader market so far in 2024. The SPDR S&P Biotech ETF, an industry benchmark, is up 9% this year compared to 28% for the S&P 500.
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
10:57am, Friday, 29'th Nov 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Exelixis (EXEL) Up 10.8% Since Last Earnings Report: Can It Continue?
12:36pm, Thursday, 28'th Nov 2024
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock?
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in December
04:05pm, Wednesday, 27'th Nov 2024
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in December: Piper Sand
ODAC to Discuss Exelixis' Application for Cabometyx Label Expansion
12:30pm, Wednesday, 27'th Nov 2024
The FDA notified EXEL that its sNDA seeking label expansion of cabozantinib will be discussed at an ODAC meeting in March 2025.
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sN
End of Year Rally: 3 Stocks to Watch (IDCC, FUTU, EXEL)
01:35pm, Tuesday, 26'th Nov 2024
As the calendar winds down, the stock market often heats up. The last five weeks of the year have historically shown a bullish seasonal pattern, fueled by holiday optimism, institutional portfolio adj
Exelixis Stock Surges 25% in a Month: Time to Buy or Sell?
02:25pm, Monday, 25'th Nov 2024
EXEL's shares move north 25% in a month on the back of strong third-quarter results and raised outlook. We are optimistic about the stock as we believe there is room for growth.
